Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for December 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Three Novel …
Read More »No Increased Fracture Risk With Canagliflozin in Type 2 Diabetes
Rate of the primary outcome was similar for canagliflozin, glucagon-like peptide-1 agonist
Read More »Three Novel Loci Associated With Polycystic Ovary Syndrome ID’d
Genetic links with obesity, T2DM, lipids suggest shared genetic architecture for PCOS, metabolic traits
Read More »Incidence of End-Stage Kidney Disease Up in Australia
Incidence increased for nonindigenous people with type 2 diabetes; greatest increase for under 50s, over 80s
Read More »Pregnancy Complications Up for Women Born at Low Birth Weight
Risk greatest for women born with birth weight <2,500 g who develop overweight/obesity
Read More »Second-Line Antidiabetic Meds May Impact Cardiovascular Risk
Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM
Read More »Targeted Muscle Reinnervation Can Reduce Phantom Limb Pain
Authors report reduction in pain and no symptomatic neuromas in 22 below-the-knee amputees
Read More »ACOG: Interpregnancy Period Should Maximize Women’s Health
Components of postpartum care should be included as the initial components of interpregnancy care
Read More »FDA Warns Companies on Unsafe, Unapproved Stem Cell Treatments
Patients contracting deadly infections at clinics offering the unapproved treatments
Read More »ADA 2019 Standards of Care Emphasize Patient-Centered Care
Updates include use of SGLT-2 inhibitors and GLP-1 receptor agonists for T2DM, CVD; endorsed by ACC
Read More »